CDK2 Inhibitors Could Enhance Immunotherapy Across Multiple Cancer Types

Researchers from Dana-Farber Cancer Institute have discovered that cyclin-dependent kinase 2 (CDK2) inhibitors, currently being tested for a limited range of cancers, could significantly broaden their therapeutic potential when combined with immunotherapy. This breakthrough suggests that targeting the CDK2 protein—which regulates cell division—may help strengthen the body's immune response against cancer cells across diverse tumor types. The combination approach could overcome current limitations of immunotherapy alone, offering hope for patients with cancers that have proven resistant to existing treatments. This research represents a promising step forward in developing more effective and widely applicable cancer treatment strategies.